Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 434 • 2015 ACR/ARHP Annual Meeting
Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients
Nicole P.C. Konijn¹, Lilian H.D. van Tuyl¹, Maarten Boers^1,2, D den Uyl¹, M.M. ter Wee¹, P.J.S.M. Kerstens^3,4, Alexandre E. Voskuyl⁵, Michael T. Nurmohamed^1,3, Dirkjan van Schaardenburg^3,6 and Willem F. Lems^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Epidemiology & Biostatistics, VU University medical center, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁴Rheumatology, Westfriesgasthuis, Hoorn, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁶Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Several sets of remission criteria have been developed. The ACR/EULAR criteria were validated against their potential to predict prognosis of rheumatoid arthritis (RA) [1].…
Abstract Number: 3187 • 2015 ACR/ARHP Annual Meeting
Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population
Bindee Kuriya¹, Xiuying Li², George A. Tomlinson³, Edward C. Keystone⁴, Claire Bombardier² and OBRI Investigators, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: The timing and severity of relapse and likelihood of “recapturing” remission following a relapse in RA is not well known. We aimed to describe…
Abstract Number: 440 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment
Yusuke Miwa¹, Ryo Takahashi¹, Airi Maeoka¹, Shinichiro Nishimi¹, Nao Oguro¹, Sho Ishii¹, Mika Kobuna¹, Takahiro Tokunaga¹, Masayu Umemura¹, Tsuyoshi Kasama¹, Katsunori Inagaki² and Yoichi Toyoshima³, ¹Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ²Department of Orthopedics, Showa University School of Med, Tokyo, Japan, ³Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Biologic agents are highly effective for rheumatoid arthritis (RA); however, not all cases achieve health assessment questionnaire (HAQ) remission. Although previous studies have reported…
Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Pongthorn Narongroeknawin¹, Wanruchada Katchamart², Parawee Suwannalai³, Nuntana Kasitanon⁴, Tasanee Kitumnuaypong⁵, Ajanee Mahakkanukrauh⁶ and Boonjing Siripaitoon⁷, ¹Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, ⁶Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, ⁷Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
Abstract Number: 448 • 2015 ACR/ARHP Annual Meeting
A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen³, Timo Yli-Kerttula⁴, Päivi Ekman⁵, Laura Pirilä⁶, Markku Mali⁷, Laura Kuusela⁷, Maija Puurtinen-Vilkki⁷, Saara Kortelainen⁸, Johanna Paltta⁷, Kirsi Taimen⁷, Heidi Mäkinen⁹, Pia Isomäki⁹, Terhi Uotila⁹, Markku J. Kauppi¹⁰, Kari Laiho¹¹, Satu Nyrhinen¹¹, Tuulikki Sokka-Isler¹ and FIN-ERA study group, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Sairaalantie 3, Central Hospital of Satakunta, Pori, Finland, ⁵Central Hospital of Satakunta, Pori, Finland, ⁶Tyks, P.O. Box 52, Turku University Central Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Alvar Aallontie 275, Turku University Central Hospital, Turku, Finland, ⁹Tampere University Hospital, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Finnish national combination treatment trials have demonstrated excellent outcomes in patients with ERA including 90% of patients reaching DAS28 remission at 6 months. Whether…
Abstract Number: 465 • 2015 ACR/ARHP Annual Meeting
MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort
Mami Tamai¹, Yoshikazu Nakashima¹, Kazuhiko Arima², Junko Kita¹, Masataka Umeda¹, Shoichi Fukui¹, Ayako Nishino¹, Takahisa Suzuki¹, Yoshiro Horai¹, Akitomo Okada³, Tomohiro Koga¹, Shin-ya Kawashiri^1,2, Naoki Iwamoto¹, Kunihiro Ichinose¹, Satoshi Yamasaki⁴, Hideki Nakamura¹, Tomoki Origuchi⁵, Kiyoshi Aoyagi², Masataka Uetani⁶, Katsumi Eguchi⁷ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Public Health, Nagasaki University, Nagasaki, Japan, ³Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁴Hiroshima University, Hiroshima, Japan, ⁵Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁶Department of Radiology and Radiation Research, Nagasaki University, Nagasaki, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan
Background/Purpose: Given the improved detection of joint injury by MRI than by clinical examination, EULAR recommendations for the use of imaging of the joints in…
Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…
Abstract Number: 563 • 2015 ACR/ARHP Annual Meeting
Abatacept Plus Methotrexate Can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis
Paul Emery¹, G Burmester², VP Bykerk³, B Combe⁴, Daniel E. Furst⁵, M Maldonado⁶ and T. W. J. Huizinga⁷, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, New York, NY, ⁴Service d’Immuno-Rheumatologie, Montpellier, France, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Assessing Very Early Rheumatoid arthritis Treatment (AVERT) was a Phase IIIb, randomized, active-controlled study to evaluate the efficacy and safety of abatacept (ABA) treatment…
Abstract Number: 620 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patients from the Non-Biologic Arms of Inflammatory Arthritis Clinical Trials Identifies Several Predictors of Remission, As Well As, Distinct Responder Subgroups
Brian Tom¹ and Deborah P.M. Symmons², ¹Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: The RA-MAP consortium is a UK flagship industry-academic partnership investigating clinical and biological predictors of disease outcome in patients with rheumatoid arthritis (RA). Methods:…
Abstract Number: 1042 • 2015 ACR/ARHP Annual Meeting
Pragmatic Multicenter Open-Label Randomized Controlled Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients in Remission or Stable Low Disease Activity in the Netherlands
Marjan Ghiti Moghadam¹, Harald E. Vonkeman², Peter M. ten Klooster³, Janneke Tekstra⁴, Dirkjan van Schaardenburg⁵, Mirian Starmans-kool^6,7, Elisabeth Brouwer⁸, Reinhard Bos⁹, Willem F. Lems¹⁰, Edgar Colin¹¹, Cornelia F. Allaart¹², Inger L. Meek¹³, Robert B.M. Landewé¹⁴, Hein J. Bernelot Moens¹⁵, Piet van Riel¹³, Mart A.F.J. van de Laar¹⁶, Tim Jansen¹⁷ and on behalf of the Dutch National POET Collaboration., ¹rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Jan van Breemen Research Institute, Amsterdam, Netherlands, ⁶Rheumatology, Orbis Medical Center, Geleen-Sittard, Netherlands, ⁷Rheumatology, Atrium Medical center, Heerlen, Netherlands, ⁸Rheumatology, University Medical center Groningen, Groningen, Netherlands, ⁹Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹²Department of Rheumatology, Leiden Universitary Medical Center, Leiden, Netherlands, ¹³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹⁵rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands, ¹⁶Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ¹⁷VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: TNF-inhibitors (TNFi) are effective treatments of rheumatoid arthritis (RA). It is not clear if patients in remission or stable low disease activity need to…
Abstract Number: 2584 • 2015 ACR/ARHP Annual Meeting
Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment
Juergen Rech¹, Axel J. Hueber², Matthias Englbrecht², Stephanie Finzel³, Judith Haschka^4,5, Bernhard Manger², Arnd Kleyer³, Michaela Reiser³, Hans-Peter Tony⁶, Stefan Kleinert⁷, Martin Feuchtenberger⁸, Martin Fleck⁹, Karin Manger¹⁰, Wolfgang Ochs¹¹, Matthias Schmitt-Haendle¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Hanns-Martin Lorenz¹⁴, Hubert Nüßlein¹⁵, Rieke Alten¹⁶, Jayme Fogagnolo Cobra¹⁷, Joerg C. Henes¹⁸, Klaus Krüger¹⁹ and Georg A. Schett²⁰, ¹medical clinic 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medical Department II, Medical University of Vienna, St. Vincent Hospital Vienna,, Vienna, Austria, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ⁸Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁹Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁰Rheumatology Practice Bamberg, Bamberg, Germany, ¹¹Rheumatologist in Private Practice, Bayreuth, Germany, ¹²Rheumatology Practice, Bayreuth, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴University Hospital Heidelberg, Heidelberg, Germany, ¹⁵University Erlangen, Nürnberg, Germany, ¹⁶Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ¹⁷Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ¹⁹Praxiszentrum St. Bonifatius, München, Germany, ²⁰University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To analyze the role of multi-biomarker disease activity (MBDA) in predicting disease relapses in rheumatoid arthritis (RA) patients in sustained remission, tapering disease modifying…
Abstract Number: 2608 • 2015 ACR/ARHP Annual Meeting
The “Rheumatoid Arthritis Impact of Disease”� Score Correlates with Other Patient Reported Outcomes and with Disease Activity Scores in Patients with RA and Its Patient Acceptable Symptom State Is More Stringent Than DAS28-Remission
Ricardo J.O. Ferreira^1,2, Cátia Duarte^1,3, Sylvie Batista³, Catarina Medeiros³, J.P. Sousa³, Gisela Eugénio¹, Carlos Costa¹, Pedro Carvalho¹, Joana F. Ferreira¹, Margarida Coutinho^1,4, Maria J. Salvador^1,4, Laure Gossec⁵ and J.A.P. da Silva^3,6, ¹Rheumatology, Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal, ²Health Sciences Research Unit: Nursing (UICISA: E), Coimbra, Portugal, ³Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, ⁴Clínica Universitária de Reumatologia, Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, ⁵Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁶Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal
Background/Purpose: The "Rheumatoid Arthritis Impact of Disease" (RAID) score is a Patient Reported Outcome (PRO) that comprises seven domains of disease[1], that may reflect the…
Abstract Number: 2619 • 2015 ACR/ARHP Annual Meeting
Clinical Usefulness of Periodic Detection of Serum 14-3-3Î· for Predicting Efficacy of Tocilizumab in RA
Akira Sagawa¹, Takuya Isayama², Makoto Kaneda³, Yuan Gui⁴, Anthony Marotta⁵ and Jiro Arai², ¹Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ²Medical and Biological Laboratories Co., Ltd., Ina, Japan, ³MBL Europe, Diegem, Belgium, ⁴Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose: Serum 14-3-3η is a diagnostic marker for RA. Recent in vitro evidence indicates that it may play a casual role in the pathogenesis of…
Abstract Number: 2652 • 2015 ACR/ARHP Annual Meeting
Power Doppler Ultrasound Features in Rheumatoid Arthritis Patients in Clinical Remission: Reclassifying Disease Activity?
Facundo Vergara¹, Santiago Ruta¹, Maria de los Angeles Gallardo¹, Emmanuel Bertiller², Josefina Marin¹, Javier Rosa³, Ricardo Garcia-Monaco⁴ and Enrique R. Soriano⁵, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ³Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Many studies have shown disparity between clinical and ultrasound (US) findings in rheumatoid arthritis (RA). US appears to detect subclinical synovitis in patients in…
Abstract Number: 2814 • 2014 ACR/ARHP Annual Meeting
Time-to-Remission, Time-to-Relapse and Disease Severity at the Time of Relapse in RA- Results from the Ontario Best Practices Research Initiative (OBRI)
Bindee Kuriya¹, Xiuying Li², Binu Jacob², Pooneh Akhavan³, Jessica Widdifield⁴, Mark Tatangelo⁵, Janet E. Pope⁶, Edward Keystone⁷ and Claire Bombardier⁸, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴200 Elizabeth St, University of Toronto, Toronto, ON, Canada, ⁵Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶Medicine, Western University, London, ON, Canada, ⁷Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: Clinical remission in RA is the desired goal, however the ability to sustain remission and the timing and severity of relapse is not well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].